KLK3 and cancer: In this study, we observed at three months of follow-up a decrease in the PSA level in surviving patients (low risk cancer) with a mean PSA level of 28.44 ng/ml (range: 6.5 and 89.32 ng/ml), while in deceased patients the mean PSA level was 357.66 ng/ml (range: 88.13 and 1782.10 ng/ml).